Combined Inhibition of Gαq and MEK Enhances Therapeutic Efficacy in Uveal Melanoma
Abstract
All uveal melanoma and a fraction of other melanoma subtypes are driven by activation of the G-protein alpha-q (Gαq) pathway. Targeting these melanomas has proven difficult despite advances in the molecular understanding of key driver signaling pathways in the disease pathogenesis. Inhibitors of Gαq have shown promising preclinical results, but their therapeutic activity in distinct Gαq mutational contexts and in vivo have remained elusive.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 01, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-2860
Entities
People
- Alexander N Shoushtari
- Amanda R Moore
- Barry S. Taylor
- Cindy J. Lee
- Emilie Ceraudo
- Gabriella Bayshtok
- Jasmine H Francis
- Matthew T. Chang
- Mohini R. Pachai
- Naitao Wang
- Ping Chi
- Ruobing Jia
- Thomas Huber
- Thomas P Sakmar
- Tyler D. Hitchman
- Youxin Guan
- Yu Chen
Organizations
- Cornell University
- Israel National Road Safety Authority
- Karolinska Institutet
- Memorial Sloan Kettering Cancer Center
- National Cancer Institute
- Prostate Cancer Foundation
- Shanghai Jiao Tong University
- The Rockefeller University
- United States Department of Defense
- University of California, San Francisco
- Weill Cornell Medicine